» Journals » Cancer Gene Ther

Cancer Gene Therapy

Cancer Gene Therapy is a peer-reviewed journal dedicated to advancing the field of gene therapy for cancer treatment. It publishes cutting-edge research on the development and application of gene-based therapies, including viral vectors, gene editing technologies, and immunotherapies. The journal aims to provide a platform for scientists, clinicians, and researchers to share their findings and contribute to the progress of this promising field in the fight against cancer.

Details
Abbr. Cancer Gene Ther
Start 1994
End Continuing
Frequency Twelve no. a year, 2000-
p-ISSN 0929-1903
e-ISSN 1476-5500
Country United Kingdom
Language English
Metrics
h-index / Ranks: 3170 99
SJR / Ranks: 2060 1457
CiteScore / Ranks: 1684 9.30
JIF / Ranks: 997 6.4
Recent Articles
1.
Cervera S, Martinez S, Iranzo-Martinez M, Notario L, Melero-Fernandez de Mera R, Alonso J
Cancer Gene Ther . 2025 Mar; PMID: 40089636
We have recently demonstrated that genetic inactivation of EWSR1 : : FLI1 by CRISPR/Cas9, successfully blocks cell proliferation in a cell model of Ewing sarcoma. However, CRISPR/Cas9-mediated gene editing can...
2.
Cheng Y, Xiao Z, Cai W, Zhou T, Yang Z
Cancer Gene Ther . 2025 Mar; PMID: 40075208
Elevated levels of androgens in the brain accelerate tumor progression in patients with glioblastoma (GBM). Despite current research efforts concentrating on decreasing peripheral androgens to improve GBM prognosis, results have...
3.
Dai Z, Si Y, Xiong S, Li Y, Ye J, Gao Q, et al.
Cancer Gene Ther . 2025 Mar; PMID: 40057574
KD01, a third-generation conditionally replicating adenovirus serotype 5 developed by our team, has approved by the China Center for Drug Evaluation (CDE) for Phase I clinical trials (NCT06552598). However, 60%...
4.
Gao Y, Tang Y
Cancer Gene Ther . 2025 Mar; PMID: 40057573
The prohibitin (PHB) family, including PHB1 and its homolog PHB2, is ubiquitously located in different cellular compartments and plays roles in fundamental cellular processes such as proliferation, differentiation, and apoptosis....
5.
Li W, Ji T, Ye J, Xiong S, Si Y, Sun X, et al.
Cancer Gene Ther . 2025 Mar; PMID: 40033102
Oncolytic virotherapy has emerged as a promising strategy for cancer treatment by selectively targeting and lysing tumor cells. However, its efficacy is often limited in certain tumor types due to...
6.
Iizuka T, Zuberi A, Wei H, Coon V J, Anton M, Buyukcelebi K, et al.
Cancer Gene Ther . 2025 Mar; PMID: 40025195
Approximately 77.4% of uterine leiomyomas carry MED12 gene mutations (mut-MED12), which are specifically associated with strikingly upregulated expression and activity of the tryptophan 2,3-dioxygenase (TDO2) enzyme, leading to increased conversion...
7.
A R, Ueki H, Nishioka S, Yamazaki R, Maekawa M, Kitagawa K, et al.
Cancer Gene Ther . 2025 Feb; PMID: 40011711
Muscle-invasive bladder cancer (MIBC), a highly heterogeneous disease, shows genomic instability and a high mutation rate, making it difficult to treat. Recent studies revealed that cancer stem cells (CSCs) play...
8.
Yu Z, Fu J, Mantareva V, Blazevic I, Wu Y, Wen D, et al.
Cancer Gene Ther . 2025 Feb; PMID: 40011710
Tumor metastasis regulated by multiple complicated pathways is closely related to variations in the tumor microenvironment. Exosomes can regulate the tumor microenvironment through various mechanisms. Exosomes derived from tumor cells...
9.
Mao Y, Hu Y, Meng H, Qin J, An Q, Zhang C, et al.
Cancer Gene Ther . 2025 Feb; PMID: 39984673
Gastric cancer (GC) is the third leading cause of cancer-related mortality and the fourth most prevalent malignancy globally. The high prevalence and mortality rates of GC are attributed to various...
10.
Trejo-Villegas O, Pineda-Villegas P, Armas-Lopez L, Mendoza-Milla C, Peralta-Arrieta I, Arrieta O, et al.
Cancer Gene Ther . 2025 Feb; PMID: 39971779
Lung cancer remains the leading cause of cancer-related mortality globally, with genes such as SMARCB1, MEOX2, and GLI-1 playing significant roles in its malignancy. Despite their known involvement, the specific...